A new medication is on the market for type 2 diabetics. Synjardy was approved for use in Europe in May, and now will be stocking American pharmacy shelves.
What Is Synjardy?
Synjardy combines metformin with what is known as an SGLT2 inhibitor. Metformin is the most common oral medication for type 2 diabetics, and its purpose is to help lower insulin resistance in conjunction with diet and exercise.
SGLT2, which stands for 'sodium glucose cotransporter 2,' help lower blood sugar by helping kidneys expel it through urination.
Synjardy comes with some concerns. According to the FDA, it may lead to ketoacidosis or high levels of ketones in the blood. Ketoacidosis is a life-threatening condition, so those who are using Synjardy are urged to talk to keep an eye out for symptoms of ketoacidosis.
Because type 1 diabetics are more at risk for ketoacidosis, Synjardy is not recommended for them.
Photo: Diabetes News Journal